
30-Country IVD Market Atlas, 2024 (In Vitro Diagnostic Markets for US, China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, Turkey and 20 Other Countries)
Description
30-Country IVD Market Atlas, 2024 (In Vitro Diagnostic Markets for US, China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, Turkey and 20 Other Countries)
What’s Included
- One Report Covering 30 Countries
- Sizing for 20 Important IVD Market Segments
- Segments Estimated for Each Country
- Forecasts to 2028 for Each Segment
- Updated Quarterly (4 updates annually) to Reflect Market Changes
- Over 2800 Data Points
With over two decades of experience in publishing in vitro diagnostic (IVD) market research, Kalorama Information understands the importance of global coverage and the need for more detailed geographic analysis. While regional coverage is valuable, it often falls short of providing a complete picture. This is why we are offering a unique approach focused on country-level research and analysis in our 30 Country In Vitro Diagnostics (IVD) Market Atlas, 2024.
This quarterly updated report provides a detailed analysis of the major IVD segments forecasted for five years, covering 30 countries. To replicate the depth of data found in the IVD Market Atlas, one would need to purchase numerous individual market research studies from other companies. This report aligns with Kalorama’s expert global estimates in our annual Worldwide Market for In Vitro Diagnostics, offering segmented market analysis for 30 important country markets and 20 key test segments. Global country market coverage includes:
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- Egypt
- France
- Germany
- India
- Indonesia
- Italy
- Japan
- Mexico
- Netherlands
- Poland
- Romania
- Russia
- Saudi Arabia
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- United States
- Vietnam
- General Chemistries
- Critical Care (core lab)
- Hematology
- Coagulation PT/Routine
- Immunoassays – Micro
- Immunoassays - Non-Micro
- Blood Bank Screening - Immunos
- Microbiology – ID/AST
- Molecular Respiratory
- Molecular Bloodstream/HAI
- Molecular HIV & Hepatitis
- Molecular - Other¹
- POC Glucose (all)
- POC Critical Care
- POC Infectious Disease (all)
- POC Pregnancy & Fertility
- POC Fecal Occult
- Other POC
- Histology
- Other IVD
The report is updated every quarter to reflect market changes. Factors such as COVID-19, international developments, M&A activity, new products, point-of-care trends, and regulatory changes have increased the pace of change in the IVD market. While significant market shifts may not occur every quarter, the report ensures that you have the most up-to-date data for your business planning.
Subscribers will receive quarterly updates through our Knowledge Center product.
Table of Contents
75 Pages
- IVD Market Demand and Growth
- Scope and Methodology
- Market Segmentation
- United States IVD Market Overview
- Germany IVD Market Overview
- China IVD Market Overview
- Japan IVD Market Overview
- France IVD Market Overview
- United Kingdom IVD Market Overview
- Italy IVD Market Overview
- Canada IVD Market Overview
- Spain IVD Market Overview
- Australia IVD Market Overview
- Brazil IVD Market Overview
- India IVD Market Overview
- Russia IVD Market Overview
- Netherlands IVD Market Overview
- Switzerland IVD Market Overview
- Poland IVD Market Overview
- Turkey IVD Market Overview
- Sweden IVD Market Overview
- Mexico IVD Market Overview
- Belgium IVD Market Overview
- Austria IVD Market Overview
- Saudi Arabia IVD Market Overview
- South Korea IVD Market Overview
- Egypt IVD Market Overview
- Romania IVD Market Overview
- South Africa IVD Market Overview
- Indonesia IVD Market Overview
- Chile IVD Market Overview
- United Arab Emirates IVD Overview
- Vietnam IVD Market Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.